New insights into cytotoxic mechanisms of bozepinib against glioblastoma.

Abstract

Glioblastoma (GBM) is the most frequent and aggressive brain tumor in adults and the current treatments only have a modest effect on patient survival. Recent studies show that bozepinib (BZP), a purine derivative, has potential applications in cancer treatment. The aim of this study was to evaluate the effect of BZP against GBM cells, specially concerning the purinergic system. Thus, GBM cells (C6 and U138 cell lines) were treated with BZP and cell viability, cell cycle, and annexin/PI assays, and active caspase-3 measurements were carried out. Besides, the effect of BZP over the purinergic system was also evaluated in silico and in vitro. Finally, we evaluate the action of BZP against important markers related to cancer progression, such as Akt, NF-κB, and CD133. We demonstrate here that BZP reduces GBM cell viability (IC50 = 5.7 ± 0.3 µM and 12.7 ± 1.5 µM, in C6 and U138 cells, respectively), inducing cell death through caspase-dependent apoptosis, autophagosome formation, activation of NF-κB, without any change in cell cycle progression or on the Akt pathway. Also, BZP modulates the purinergic system, inducing an increase in CD39 enzyme expression and activity, while inhibiting CD73 activity and adenosine formation, without altering CD73 enzyme expression. Curiously, one cycle of treatment resulted in enrichment of GBM cells expressing NF-κB and CD133+, suggesting resistant cells selection. However, after another treatment round, the resistant cells were eliminated. Altogether, BZP presented in vitro anti-glioma activity, encouraging further in vivo studies in order to better understand its mechanism of action.

• Authors: Amanda de Fraga Dias, Juliete Nathali Scholl, Cesar Eduardo Jacintho Moritz, Luciano Porto Kagami, Gustavo Machado das Neves, Vera Lúcia Eifler-Lima, Olga Cruz-López, Ana Conejo-García, Jean Sévigny, Ana Maria Oliveira Battastini, Joaquin María Campos, Fabrício Figueiró
• Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences (Eur J Pharm Sci) Vol. 162 Pg. 105823 (Jul 01 2021) ISSN: 1879-0720 [Electronic] Netherlands
• PMID: 33781855 (Publication Type: Journal Article)
• Copyright: Copyright © 2021 Elsevier B.V. All rights reserved.

Chemical References

• 2,6-dichloro-9-(1-(p-nitrobenzenesulfonyl)-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl)-9H-purine
• Oxazepines
• Purines

Topics

• Apoptosis
• Brain Neoplasms (drug therapy)
• Cell Line, Tumor
• Cell Proliferation
• Glioblastoma (drug therapy)
• Humans
• Oxazepines
• Purines